Trial Profile
A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Leramistat (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Istesso
- 15 Jul 2022 Results presented in an Istesso Media Release.
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.